Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 10/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13928032 | 0.88 | MLNR (0.70) | MLNRCYP3A4KMT2ACYP2D6 | |
| SCHEMBL1704619 | 0.82 | MLNR (1.00) | MLNRCYP3A4CYP2D6 | |
| SCHEMBL13504053 | 0.80 | SMN1; SMN2 (0.69) | KMT2AALDH1A1MAPTHPGDLMNA | |
| SCHEMBL1704769 | 0.79 | MLNR (1.00) | MLNRCYP3A4CYP2D6 | |
| SCHEMBL13928035 | 0.79 | MLNR (0.70) | MLNRCYP3A4CYP2D6 | |
| SCHEMBL13928034 | 0.79 | MLNR (0.70) | MLNRCYP3A4POLB | |
| SCHEMBL14028152 | 0.77 | POLB (0.73) | KMT2AALDH1A1MAPTHPGDLMNA | |
| SCHEMBL13928027 | 0.76 | KMT2A (0.59) | KMT2AALDH1A1MAPTHPGDLMNA | |
| SCHEMBL23252437 | 0.74 | HRH3 (0.64) | KMT2AALDH1A1MAPTHPGDLMNA | |
| SCHEMBL1704131 | 0.72 | MLNR (1.00) | MLNRCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GPR68, GPR88, GPR55 | MLNR 87/4885CYP3A4 606/4885KMT2A 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.